DNM2 Recombinant Monoclonal Antibody

Code CSB-RA877222A0HU
Size US$210
Order now
Image
  • Western Blot
    Positive WB detected in: HL60 whole cell lysate, Rat brain tissue
    All lanes: DNM2 antibody at 1:2000
    Secondary
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 99, 98 kDa
    Observed band size: 99 kDa
  • Immunofluorescence staining of Hela Cells with CSB-RA877222A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeated by 0.2% TritonX-100, and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4℃. Nuclear DNA was labeled in blue with DAPI. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L).
  • Overlay histogram showing Hela cells stained with CSB-RA877222A0HU (red line) at 1:50. The cells were fixed with 70% Ethylalcohol (18h) and then incubated in 10% normal goat serum to block non-specific protein-protein interactions followedby the antibody (1µg/1*106 cells) for 1 h at 4℃.The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 30min at 4℃. Control antibody (green line) was Rabbit IgG (1µg/1*106 cells) used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
DNM2
Alternative Names
Dynamin-2 (EC 3.6.5.5), DNM2, DYN2
Species Reactivity
Human, Rat
Immunogen
A synthesized peptide derived from human Dynamin 2
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Isotype
Rabbit IgG
Clone No.
1D8
Purification Method
Affinity-chromatography
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Form
Liquid
Tested Applications
ELISA, WB, IF, FC
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IF 1:20-1:200
FC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

DNM2 is a force-generating GTPase that catalyzes membrane constriction and fission. It is involved in endocytosis and intracellular membrane trafficking. Charcot-Marie-Tooth disease (CMT) and centronuclear myopathy (CNM), both autosomal-dominant motor illnesses, are linked to mutations in the DNM2 gene. DNM2 involvement, via mutations or overexpression, has been found in an increasing number of malignancies and is frequently linked to dismal prognosis.

The recombinant DNM2 antibody is a monoclonal antibody generated by cloning DNM2 antibody genes into plasma vectors and transfecting vector clones into stable cell lines for production. For recombinant antibody generation, mammalian cell lines like CHO cells and HEK293 are commonly used. The recombinant DNM2 antibody was purified using Affinity-chromatography. It has verified to detect DNM2 protein from Human, Rat in the ELISA, WB, IF, FC.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Microtubule-associated force-producing protein involved in producing microtubule bundles and able to bind and hydrolyze GTP. Plays a role in the regulation of neuron morphology, axon growth and formation of neuronal growth cones. Plays an important role in vesicular trafficking processes, in particular endocytosis. Involved in cytokinesis. Regulates maturation of apoptotic cell corpse-containing phagosomes by recruiting PIK3C3 to the phagosome membrane.
Gene References into Functions
  1. DNM2 is a substrate for CDK1-dependent phosphorylation, which plays an important role in the regulation of human sperm acrosomal exocytosis. PMID: 29044420
  2. Data found DNM2 highly expressed compared in both forms of ALL and associated with poor prognosis and with tumor cell proliferation. Also, Ikaros directly binds the DNM2 promoter and suppresses its expression. PMID: 27885263
  3. a new AHI-1-BCR-ABL-DNM2 protein complex was uncovered, which regulates leukemic properties of these cells through a unique mechanism of cellular endocytosis and ROS-mediated autophagy. Thus, targeting this complex may facilitate eradication of LSCs for curative therapies PMID: 28366933
  4. dynamin-2, as a tetramer, might help to establish hemi-fusion and stabilizes the pore during HIV-1 fusion. PMID: 28076788
  5. Data suggest DNM2/RRAGB- (or DNM2/RRAGC-)dependent endocytosis of extracellular amino acids (AAs) plays critical role in mTORC1 transport/activation; recruitment of mTORC1 from cytoplasm to lysosome is suppressed by DNM2 inhibition; AA deprivation appears to be main cause of mTORC1 inactivation via DNM2 inhibition. (RHEB = Ras homolog enriched in brain; DNM2 = dynamin II; RRAG = Ras-related GTP binding protein) PMID: 28808055
  6. We demonstrate that the dynamin2 effect on T cell adhesion does not involve integrin affinity regulation but instead relies on its ability to modulate integrin valency. PMID: 28273099
  7. Thus, dynamin2 contributes to bladder cancer invasion by controlling invadopodia formation in bladder cancer cells and may prove a valuable therapeutic target. PMID: 27771248
  8. Study showed that dynamin 2 and cortactin participate in the formation of F-actin bundles, which stabilize filopodia in migrating cancer cells. PMID: 27572123
  9. Data demonstrate that dynamin II is required for the E2:ERalpha signaling of physiological functions and uncovers a role for autophagy in the control of ERalpha turnover. PMID: 27009360
  10. This study reported the clinical characteristics, molecular diagnosis strategy, and DNM2 gene mutations of four Chinese Han patients with centronuclear myopathy. PMID: 26908122
  11. Results demonstrate that overexpression of human DNM2 mRNAs, containing different disease-related mutations, cause a continuum of pathological features in zebrafish similarly to what observed in human centronuclear myopathies and neuropathies. PMID: 26842864
  12. uncover a link between the dynamin 2 function and JNK signaling which leads to AP-1 induction PMID: 26475677
  13. results provide evidence for a novel Arf6 activation mechanism by Dyn2 through EFA6B and EFA6D in CME in a manner dependent upon the GTPase activity of Dyn2 PMID: 26503427
  14. We conclude that DNM2 is a novel negative regulator of NO production in mouse collecting ducts. PMID: 26791826
  15. In marked contrast to invadopodia, this degradation does not require the action of Src kinase, Cdc42 or Dyn2. Rather, inhibition of Dyn2 causes a marked upregulation of stromal matrix degradation PMID: 25982272
  16. exome sequencing family study reveals that autosomal dominant spastic paraplegia linked to a GTPase-effector domain mutation of dynamin 2 PMID: 26517984
  17. This study demonistrated that DNM2 mutation releated to Centronuclear myopathy. PMID: 25957634
  18. Dynamin 2 deletion in beta cells caused glucose intolerance and reduced the 2d phase of glucose-stimulated insulin secretion. Dynamin 2 regulates insulin secretory capacity and dynamics in vivo via a mechanism depending on CME and F-actin remodeling. PMID: 26413867
  19. this study described for the first time the clinical, pathological and genetic features of DNM2-related CNM in Chinese patients. PMID: 25501959
  20. Data indicate that dynamin 2 (Dyn2) interacts with Connexin 26 (Cx26) in a yeast two-hybrid screen, and co-localizes in mammalian cells. PMID: 25263585
  21. Dynamin 2 is recruited as dimers during endocytic membrane scission at the neck of a clathrin-coated pit. PMID: 25232009
  22. Thus dynamin that was recently found to control late stages of myoblast fusion also controls late stages of macrophage fusion, revealing an intriguing conserved mechanistic motif shared by diverse cell-cell fusion processes. PMID: 25336256
  23. FGF21 has a role in promoting endothelial cell angiogenesis through a dynamin-2 and Rab5 dependent pathway PMID: 24848261
  24. Inhibition of Dyn2 prevents cell invasiveness in androgen-responsive and -refractory PCA models, supporting the potential benefit of Dyn2 to serve as a therapeutic target for advanced prostate cancer . PMID: 24402972
  25. These results reveal that girdin regulates selective clathrin-mediated endocytosis via a mechanism involving dynamin 2, but not by operating as a cargo-specific adaptor. PMID: 25061227
  26. Upon overexpression of dynamin-2 mutants or depletion of clathrin heavy chain, flotillins are permanently trapped in endosomes. PMID: 24809731
  27. dynamin2 recruitment is regulated by actin polymerization PMID: 24891602
  28. Results indicate that hSNF5 affects both the stability and the activity of DNM2, uncovering an unexpected role of hSNF5 in modulating endocytosis, and open new perspectives in understanding the role of hSNF5 in tumour genesis. PMID: 23851497
  29. results demonstrate a regulatory relationship between DNM2, miR-199a, and HIF, with implications in cancer metastasis PMID: 24706848
  30. A mutation associated with centronuclear myopathy enhances the size and stability of dynamin 2 complexes. PMID: 24016602
  31. These findings provide new evidence for the participation of the autolysosome in hepatocyte lipid droplet metabolism and demonstrate a novel role for dynamin2 in the function and maturation of an autophagic compartment. PMID: 24145164
  32. Dual role of BAR domain-containing proteins in regulating vesicle release catalyzed by the GTPase, dynamin-2. PMID: 23861397
  33. We identify dynamin and the EAP-binding alpha-adaptin appendage domain of the AP2 adaptor as switches in a regulated, multistep maturation process and provide direct evidence for a molecular checkpoint in clathrin mediated endocytosis. PMID: 23891661
  34. The first homozygous mutation in the DNM2 protein p.Phe379Val, in three consanguineous patients with a lethal congenital syndrome, is reported. PMID: 23092955
  35. Three novel DNM2 mutations in an Italy cohort of centronuclear myopathy patients. PMID: 23394783
  36. This mutation (D614N) within the DNM2 gene in a large centronuclear myopathy family with a late age of overt clinical manifestation caused profound changes in DNM2 localization and impaired proper organization of myofibers and skeletal muscle function. PMID: 23374900
  37. New onset strabismus and a history of a myopathy should consider this entity in the differential diagnosis that could be confirmed by a muscle biopsy and mutational analysis. PMID: 22924779
  38. study provides evidence the large GTPase Dyn2 regulates the small GTPase Rac1 to potentiate invasive migration of pancreatic tumor cells; Dyn2 plays an essential role in regulating Rac1-mediated pancreatic tumor cell migration through modulation of the Rac1 activator Vav1 via a direct interaction PMID: 23537630
  39. investigation of dynamin 2 expression in cervix of patients with suspected cervical intraepithelial neoplasia; evaluation of dynamin 2 expression as biological marker in diagnosis/staging/grading of cervical intraepithelial neoplasia PMID: 22959143
  40. Dynamin II function is required for EGF-mediated Stat3 activation but not Erk1/2 phosphorylation PMID: 22574813
  41. clinicopathological features of DNM2 centronuclear myopathy are rather homogeneous and can be distinguished from the features of non-DNM2 centronuclear myopathy PMID: 22613877
  42. Caveolin-1 and dynamin-2 are essential for removal of the complement C5b-9 complex via endocytosis. PMID: 22528500
  43. Defects in membrane trafficking due to DNM2 mutations potentially represent a common pathological mechanism in CNM and CMT. PMID: 22396310
  44. DNM2 mutations cause autosomal dominant centronuclear myopathy or autosomal dominant (AD) Charcot-Marie-Tooth (CMT) disease; one large Czech family with 15 members affected with an AD CMT phenotype of extraordinary variability is reported. PMID: 22091729
  45. this study identifies Dyn2 as an effector that mediates PDGFRalpha-SHP-2-induced glioma tumor growth and invasion PMID: 21996738
  46. tumor cells overexpressing Dyn2 protruded lamellipodia at twice the rate, migrated faster (180%) and farther (2.5-fold greater distance) on glass and through transwell chambers PMID: 21841817
  47. The alteration of microtubules by dynamin2 depletion reduced the length and the speed of the actin comet. PMID: 22174845
  48. The mild functional defects are suggestive of differences between CMT and CNM disease-causing dynamin 2 mutants and suggest that a slight impairment in clathrin-mediated pathways may accumulate over time to foster the respective human diseases. PMID: 22096584
  49. In summary, these results suggested that dynamin 2 might play a role in HIV-1 Env-mediated cell-cell fusion. PMID: 21338326
  50. The deletion of PRD domain of dynamin 2 resulted in the impairment of both the localization and the abscission of daughter cells. PMID: 21150131

Show More

Hide All

Involvement in disease
Myopathy, centronuclear, 1 (CNM1); Lethal congenital contracture syndrome 5 (LCCS5); Charcot-Marie-Tooth disease, dominant, intermediate type, B (CMTDIB); Charcot-Marie-Tooth disease 2M (CMT2M)
Subcellular Location
Cytoplasm. Cytoplasm, cytoskeleton. Cell junction. Membrane, clathrin-coated pit. Cell junction, synapse, postsynaptic density. Cell junction, synapse. Midbody. Cell projection, phagocytic cup. Cytoplasmic vesicle, phagosome membrane; Peripheral membrane protein.
Protein Families
TRAFAC class dynamin-like GTPase superfamily, Dynamin/Fzo/YdjA family
Tissue Specificity
Ubiquitously expressed.
Database Links

HGNC: 2974

OMIM: 160150

KEGG: hsa:1785

STRING: 9606.ENSP00000347890

UniGene: Hs.211463

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*